STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis (NASDAQ: IONS) awards 10,753 stock options to director Hantson

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share. The options were granted at no cost as director compensation, vesting in three equal annual installments starting on June 4, 2027, and will be fully vested by June 4, 2029. The options expire on June 4, 2036, and were not exercisable as of the grant date.

Positive

  • None.

Negative

  • None.
Insider HANTSON LUDWIG
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 10,753 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 10,753 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 10,753 options Non-qualified stock option grant on June 4, 2026
Exercise price $75.13 per share Strike price for underlying common stock
Shares following transaction 10,753 derivative securities Total options held after this grant
Vesting start date June 4, 2027 First one-third of options vest
Full vesting date June 4, 2029 Options become fully vested and exercisable
Expiration date June 4, 2036 Option term ends
Exercisable at grant 0 shares Exercisable as of June 4, 2026
Grant price paid $0.00 per option Awarded as compensation, not purchased in market
Non-Qualified Stock Option (right to buy) financial
"security_title: Non-Qualified Stock Option (right to buy)"
Amended & Restated 2002 Non-Employee Directors' Stock Option Plan financial
"Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan."
vests and becomes exercisable financial
"The option vests and becomes exercisable in three equal annual installments"
exercise price financial
"conversion_or_exercise_price: 75.1300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HANTSON LUDWIG
(Last)(First)(Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CALIFORNIA 92010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$75.1306/04/2026A10,75306/04/2027(1)06/04/2036(1)Common Stock10,753$0.010,753D
Explanation of Responses:
1. Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026.
By: Patrick R. O'Neil, attorney-in-fact For: Ludwig Hantson06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Ludwig Hantson receive in this Ionis (IONS) Form 4 filing?

Ludwig Hantson received a grant of 10,753 non-qualified stock options. These options give him the right to buy Ionis common shares at a fixed price as part of his compensation as a non-employee director.

What is the exercise price of Ludwig Hantson’s new Ionis stock options?

The options have an exercise price of $75.13 per share. This means Hantson can purchase Ionis common stock at $75.13 per share once the options vest and become exercisable, regardless of the future market price.

How do the 10,753 Ionis stock options granted to Ludwig Hantson vest?

The options vest in three equal annual installments beginning on June 4, 2027. One-third vests each year, and the grant will be fully vested and exercisable by June 4, 2029, assuming continued service as a non-employee director.

When do Ludwig Hantson’s Ionis stock options expire?

The non-qualified stock options expire on June 4, 2036. If Hantson does not exercise the vested options by that date, they will lapse and can no longer be used to purchase Ionis common stock under this award.

Were any of Ludwig Hantson’s Ionis options exercisable on the grant date?

No, none of the options were exercisable on the grant date of June 4, 2026. The filing states the stock option was exercisable as to 0 shares at that time, with vesting beginning one year later.

Under which plan were Ludwig Hantson’s Ionis options granted?

The options were granted under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. This plan provides equity-based compensation to outside directors instead of traditional cash-only fees.